U.S., Nov. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07234864) titled 'Study to Assess Safety, Tolerability, PK, and PD of Multiple Doses of ZE63-0302 Administrated Orally in T2DM Patients.' on Sept. 25.
Brief Summary: A Phase 1b study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple doses of ZE63-0302 administrated orally in T2DM patients.
Study Start Date: Nov., 2025
Study Type: INTERVENTIONAL
Condition:
Type 2 Diabetes
Intervention:
DRUG: ZE63-0302
Oral capsules BID
DRUG: Placebo
Oral capsules BID
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Eilean Therapeutics
Published by HT Digital Content Services with permission from Health Daily ...